Preclinical evaluation of an unconventional ruthenium-gold-based chemotherapeutic: RANCE-1, in clear cell renal cell carcinoma.

Benelita T ElieKaren HubbardYuriy PechenyyBuddhadev LayekSwayam PrabhaMaria Contel

Published in: Cancer medicine (2019)

The tumor growth inhibition displayed and favorable pathology profile of RANCE-1 makes it a promising candidate for further evaluation toward clinical use for the treatment of advanced CCRCC.

Keyphrases

cell therapy
stem cells
combination therapy
bone marrow
mesenchymal stem cells
smoking cessation
clinical evaluation